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Abstract
Background: Obesity and inactivity are associated with increased risk of cancer-related and overall mortality in breast cancer,
but there are few data in metastatic disease. Methods: Cancer and Leukemia Group B 40502 was a randomized trial of first-
line taxane-based chemotherapy for patients with metastatic breast cancer. Height and weight were collected at enrollment.
After 299 patients enrolled, the study was amended to assess recreational physical activity (PA) at enrollment using the
Nurses’ Health Study Exercise Questionnaire. Associations with progression-free survival (PFS) and overall survival (OS) were
evaluated using stratified Cox modeling (strata included hormone receptor status, prior taxane, bevacizumab use, and treat-
ment arm). All statistical tests were 2-sided. Results: A total of 799 patients were enrolled, and at the time of data lock,
median follow-up was 60 months. At enrollment, median age was 56.7 years, 73.1% of participants had hormone receptor–
positive cancers, 42.6% had obesity, and 47.6% engaged in less than 3 metabolic equivalents of task (MET) hours of PA per
week (<1 hour of moderate PA). Neither baseline body mass index nor PA was statistically significantly associated with PFS or
OS, although there was a marginally statistically significant increase in PFS (hazard ratio ¼ 0.83, 95% confidence interval ¼
0.79 to 1.02; P¼ .08) and OS (hazard ratio ¼ 0.81, 95% confidence interval ¼ 0.65 to 1.02; P¼ .07) in patients who reported PA
greater than 9 MET hours per week vs 0-9 MET hours per week. Conclusions: In a trial of first-line chemotherapy for meta-
static breast cancer, rates of obesity and inactivity were high. There was no statistically significant relationship between body
mass index and outcomes. More information is needed regarding the relationship between PA and outcomes.
Obesity is a well-established risk factor for poor prognosis in
women with early stage breast cancer (1-4). A meta-analysis
conducted by the World Cancer Research Fund of 82 reports
evaluating the relationship between body mass index (BMI) and
mortality in women with stage I-III breast cancer reported a 35%
increase in breast cancer–related mortality and a 41% increase
in overall mortality in women with obesity at the time of breast
cancer diagnosis as compared with women who were of normal
weight (4). The relationship between obesity and poor outcomes
was seen in both pre- and postmenopausal women. Other
meta-analyses have demonstrated that obesity is associated
with increased risk of cancer recurrence and mortality in both
hormone receptor–positive and hormone receptor–negative
breast cancers (5,6).
Although data are more limited, physical activity (PA) is also
increasingly being linked to breast cancer outcomes. A meta-
analysis of 13 cohort studies evaluating the relationship be-
tween PA after breast cancer diagnosis and mortality in individ-
uals with stage I-III breast cancer demonstrated that breast
cancer survivors who engaged higher levels of PA after cancer
diagnosis had a 37% lower risk of breast cancer–specific mortal-
ity (hazard ratio [HR] ¼ 0.63, 95% confidence interval [CI] ¼ 0.50
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to 0.78; P< .01) compared with less active breast cancer
survivors (7).
Less is known regarding the relationships between obesity
and inactivity and outcomes in individuals with metastatic
breast cancer (MBC). A few studies have evaluated the relation-
ship between BMI and progression-free survival (PFS) or overall
survival (OS) in individuals with MBC (8–12), but most reports
have focused specifically on individuals with HER2-positive
breast cancer or with brain metastases. Results of these studies
have been mixed. There is almost no information about PA pat-
terns among individuals with MBC or about the relationship be-
tween PA and cancer outcomes in this population.
We evaluated the relationships between BMI and PA pat-
terns with PFS and OS in patients participating in Cancer and
Leukemia Group B (CALGB) 40502 (13), a randomized trial com-
paring the efficacy of 3 chemotherapy regimens, in combination
with bevacizumab, as first-line therapy for patients with MBC or
locally recurrent, unresectable breast cancer.
Methods
Study Cohort
The patient cohort for this study was derived from the study
population of CALGB 40502 (NCT00785291) (13,14), a phase III
randomized trial comparing paclitaxel with nanoparticle albu-
men bound-(nab-)paclitaxel or ixabepilone þ/- bevacizumab as
first-line chemotherapy for locally recurrent or MBC.
Participants were randomly assigned 1:1:1 to paclitaxel (90 mg/
m2), nab-paclitaxel (150 mg/m2), or ixabepilone (16 mg/m2). All
chemotherapy was administered 3 weeks on, 1 week off.
Participants were also treated with bevacizumab (10 mg/kg ev-
ery 2 weeks). In March 2011, the protocol was amended to make
bevacizumab use optional; nevertheless, 97% of participants re-
ceived the agent. Eligibility criteria included the presence of
metastatic or locally recurrent breast cancer; no prior chemo-
therapy for advanced disease; being at least 12 months from ad-
juvant taxane; and having measurable disease, adequate organ
function and Eastern Cooperative Oncology Group performance
status (ECOG PS) of 1 or less, and no grade 2 or greater peripheral
neuropathy (13).
The study was open to enrollment between November 2008
and November 2011. The CALGB, ECOG, Southwest Oncology
Group, and North Central Cancer Treatment Group (NCCTG)
participated in the study (CALGB and NCCTG are now part of
the Alliance for Clinical Trials in Oncology). All participants
signed an institutional review board–approved, protocol-
specific informed consent document meeting all federal and in-
stitutional regulatory requirements. Study results have been
published previously (13).
Measures
Height and weight were collected at the time of participant en-
rollment. BMI was calculated according to the formula: BMI ¼
weight (kg)/height (m) (2). BMI categories were defined accord-
ing to the World Health Organization as underweight (<18.5 kg/
m2), normal weight (18.5-24.9 kg/m2), overweight (25-29.9 kg/
m2), and obese (30 kg/m2).
An amendment was added to the protocol after 299 partici-
pants had been enrolled requiring that participants complete
the Nurses’ Health Study Exercise Questionnaire (NHSEQ) at the
time of study enrollment. The NHSEQ captures the frequency,
type, and duration of recreational PA. Metabolic equivalents of
task (MET) hours of weekly recreational PA were calculated us-
ing the Ainsworth Physical Activity Compendium (15).
Statistical Analysis
The analysis cohort is comprised of eligible participants who
were classified as normal weight, overweight, or obese at the
time of study entry using the World Health Organization classi-
fication scheme. Given the small number of participants classi-
fied as underweight, these participants (n¼ 9) were omitted
from analyses. PA was categorized as 0-9 MET hours per week
and more than 9 MET hours per week, based on guidelines’
recommendation of 150-180 minutes of moderate-intensity PA
per week, which is consistent with 9 MET hours per week of
PA (16,17).
Chi-square tests were used to assess whether patient or dis-
ease characteristics at registration differed with respect to BMI
or PA category. PFS was defined as the time from date of ran-
domization until date of first progression or death from any
cause. Patients without documentation of a disease event were
censored at the date of their last disease evaluation. OS was de-
fined as the time from date of randomization until death due to
any cause. Stratified Cox modeling with the stratification fac-
tors treatment assignment, hormone receptor status, prior tax-
ane, and use of bevacizumab were used to assess whether PFS
or OS differed with respect to BMI or PA in the analysis cohort.
For the subgroup of patients with hormone receptor–positive
breast cancer and the group of patients with hormone receptor–
negative breast cancer, stratified log-rank tests with treatment
assignment as the stratification factor were used to assess
whether PFS or OS differed with respect to BMI or PA. Adverse
event data were collected using Common Terminology Criteria
for Adverse Events v4.0 criteria. Chi-square tests were used to
assess whether proportion of severe adverse events (grade 3 or
higher regardless of attribution) differed by BMI and PA within
treatment arms. Analyses were performed using SAS software
(version 9.4; SAS Institute Inc) on a database locked on May 3,
2017.
Data collection and statistical analyses were conducted by
the Alliance Statistics and Data Center. Data quality was en-
sured by review of data by the Alliance Statistics and Data
Center and by the study chairperson following Alliance policies.
Results
Participant Characteristics
Overall, 799 individuals were enrolled in CALGB 40502, 783 of
whom initiated protocol treatment (see Consort Diagram,
Figure 1). Of these 783 participants, 9 were found to be under-
weight and omitted from analyses. Thus, the analytic cohort for
this report is comprised of s the 774 eligible participants who
initiated protocol treatment and were classified as normal
weight, overweight, or obese at the time of study entry. Baseline
characteristics are presented in Table 1. Median age was
56.7 years, 73.1% of patients had hormone receptor–positive
cancers, 43.8% had received a taxane in the adjuvant setting,
57.5% were diagnosed with MBC at least 2 years after initial di-
agnosis, and 61.1% had an ECOG score of 0.
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BMI and Tumor and Host Characteristics
Distribution of BMI categories was similar across treatment groups
(data not shown). Median BMI was 28.6 kg/m2 (interquartile range ¼
24.7-33.1kg/m2). Overall, 26.1% of participants were classified as nor-
mal weight, 31.2% overweight, and 42.6% obese. BMI was statisti-
cally significantly associated with race and performance status.
Individuals with obesity were more likely to be Black (18.5% vs
10.9% [normal weight] and 9.5% [overweight]; P¼ .02) and less likely
to have had a disease-free interval of more than 2 years between ini-
tial diagnosis and diagnosis of metastatic disease compared with
normal weight or overweight individuals (50.9% vs 60.4% [normal
weight] and 64.0% [overweight]; P¼ .04). No statistically significant
relationship was found between BMI and tumor hormone receptor
status or the presence of visceral metastases.
Baseline BMI and Cancer Outcomes
At a median follow-up of 60months, there were 725 PFS events and
622 deaths among the 774 study participants. No statistically signifi-
cant difference in PFS was found between those patients classified
as obese (HR ¼ 1.01, 95% CI ¼ 0.83 to 1.22; P¼ .93) or overweight (HR
¼ 1.03, 95% CI ¼ 0.84 to 1.26; P¼ .77) relative to those classified as
having normal weight. Similarly, no statistically significant
difference in OS was found between those patients classified as
obese (HR ¼ 1.03, 95% CI ¼ 0.84 to 1.26; P¼ .79) or overweight (HR ¼
1.14, 95% CI ¼ 0.92 to 1.41; P¼ .24) relative to those classified as hav-
ing normal weight. Median PFS and OS were 9.8months (95% CI ¼
9.0 to 11.1) and 26.8months (95% CI ¼ 22.1 to 32.3) in patients classi-
fied as normal weight, 9.1months (95% CI ¼ 7.6 to 10.3) and
22.0months (95% CI ¼ 19.9 to 25.2) in patients classified as over-
weight, and 8.7months (95% CI ¼ 7.8 to 9.7) and 25.8months (95% CI
¼ 23.5 to 29.5) in patients classified as obese (Figure 2). Subset analy-
ses showed that these results were similar in the subsets of partici-
pants with hormone receptor–positive and hormone receptor–
negative tumors (data not shown).
Physical Activity and Tumor and Host Characteristics
Of the 774 patients included in the BMI analyses, 492 enrolled
after the activation of the protocol amendment instituting the
collection of PA data. Patient and tumor characteristics of these
participants are included in Table 2. No statistically significant
differences were found with respect to availability of PA data,
and there were no differences in PA levels across treatment
groups (data not shown). Participants engaged in a median of
3.3 MET hours per week of PA (about 1 hour of moderate inten-
sity activity per week; interquartile range ¼ 0.7-12.7 MET hours
Assessed for eligibility (n = 799)
Physical Activity Data
Analyzed (n = 176) 
 Excluded from analysis (no
baseline physical activity data
available) (n = 97)
BMI analysis (n = 273)
 Excluded underweight patients
(BMI <18.5 kg/m2) (n = 2)
Allocated to paclitaxel intervention 
(n = 283) 
 Received intervention (n = 275)
 Did not receive intervention (n = 8)
BMI analysis (n = 238)
 Excluded underweight patients
(BMI <18.5 kg/m2) (n = 3)
Allocated to ixabepilone 
intervention (n = 245) 
 Received intervention (n = 241)
 Did not receive intervention (n = 4)
Physical Activity Data
Analyzed (n = 146) 
 Excluded from analysis (no
baseline physical activity data
available) (n = 92)
Allocated to nab-paclitaxel 
intervention (n = 271) 
 Received intervention (n = 267)
 Did not receive intervention (n = 4)
BMI analysis (n = 263)
 Excluded underweight patients
(BMI <18.5 kg/m2) (n = 4)
Physical Activity Data
Analyzed (n = 170) 
 Excluded from analysis (no
baseline physical activity data
available) (n = 93)
Randomized (n = 799)
Figure 1. CONSORT diagram. BMI ¼ body mass index.
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per week). Almost 70% of participants engaged in fewer than 9
MET hours per week of PA, with 47.6% of patients engaging in
fewer than 3 MET hours per week.
Baseline PA was statistically significantly associated with
performance status (Table 2). Fewer participants who engaged
in fewer than 9 MET hours per week of PA had a performance
status of 0 compared with participants who engaged in more
than 9 MET hours per week (57.2% vs 75.7%; P< .001). No statisti-
cally significant association was found between PA and race,
age, tumor hormone receptor status, duration of disease-free
interval between diagnosis and development of metastatic dis-
ease, or presence of visceral metastases.
Baseline PA and Cancer Outcomes
After 60 months of median follow-up, 467 PFS events and 392
deaths had occurred in the 492 participants for whom baseline
PA was available. There was a marginally statistically signifi-
cant increase in PFS (HR ¼ 0.83, 95% CI ¼ 0.79 to 1.02; P¼ .08)
and OS (HR ¼ 0.81, 95% CI ¼ 0.65 to 1.02; P¼ .07) in participants
who completed more than 9 MET hours per week of PA relative
to those who completed 0-9 MET hours per week of PA
(Figure 3). Median PFS and OS were 8.0 months (95% CI ¼ 7.4 to
9.2) and 23.6 months (95% CI ¼ 20.3 to 26.5), respectively, in
participants completing 0-9 MET hours per week of PA and
9.8 months (95% CI ¼ 8.8 to 12.0) and 27.8 months (95% CI ¼ 21.5
to 35.6) in participants completing more than 9 MET hours per
week.
Among the 366 participants with hormone receptor–positive
cancers, there was a trend between PA and longer PFS (HR ¼
0.83, 95% CI ¼ 0.79 to 1.02; P¼ .16) and OS (HR ¼ 0.81, 95% CI ¼
0.65 to 1.02; P¼ .18) for those who completed more than 9 MET
hours per week of PA relative to those who completed 0-9 MET
hours per week of PA (Figure 4). Median PFS and OS were
9.5 months (95% CI ¼ 8.0 to 10.9) and 27.1 months (95% CI ¼ 24.0





(n¼ 202) (n¼ 242) (n¼ 330)
Median age (range), y 57 (23-85) 56 (34-86) 56 (28-83) .76a
Age, No. (%), y .86b
20-49 52 (25.7) 61 (25.2) 80 (24.2)
50-69 127 (62.9) 154 (63.6) 220 (66.7)
70 to 80 23 (11.4) 27 (11.2) 30 (9.1)
Sex, No. (%) .80c
Male 2 (1.0) 3 (1.2) 6 (1.8)
Female 200 (99.0) 239 (98.8) 324 (98.2)
Race, No. (%) .02b
White 167 (82.7) 206 (85.1) 251 (76.1)
Black 22 (10.9) 23 (9.5) 61 (18.5)
Other/unknown 13 (6.4) 13 (5.4) 18 (5.5)
Taxane as adjuvant therapy, No. (%) .12b
Yes 78 (38.6) 104 (43.0) 157 (47.6)
No 124 (61.4) 138 (57.0) 173 (52.4)
Visceral metastases, No. (%) .93b
Yes 159 (79.1) 193 (80.4) 262 (79.4)
No 42 (20.9) 47 (19.6) 68 (20.6)
Missing 1 2 0
Disease-free interval, No. (%) .04b
0 (de novo) 18 (8.9) 28 (11.6) 46 (13.9)
<1 y 44 (21.8) 39 (16.1) 77 (23.3)
1 y < disease-free interval < 2 y 18 (8.9) 20 (8.3) 39 (11.8)
>2 y 122 (60.4) 155 (64.0) 168 (50.9)
Clinical stage, No. (%) .70b
Not IV 20 (11.0) 20 (9.1) 27 (8.8)
IV 162 (89.0) 199 (90.9) 281 (91.2)
Missing 20 23 22
Tumor subtype, No. (%) .51b
ER and/or PR positive 153 (75.7) 178 (73.6) 235 (71.2)
ER and PR negative 49 (24.3) 64 (26.4) 95 (28.8)
ECOG performance, No. (%) .04b
0 116 (57.7) 164 (68.3) 193 (58.5)
1 78 (38.8) 71 (29.6) 126 (38.2)
Missing 8 7 11
aTwo-sided Wilcoxon rank sum test or Kruskal-Wallis test. ECOG ¼ Eastern Cooperative Oncology Group; ER ¼ estrogen receptor; PR ¼ progesterone receptor.
bTwo-sided v2 test.
cTwo-sided Fisher exact test.
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to 32.3), respectively, in participants who completed 0-9 MET
hours per week of PA and 11.7 months (95% CI ¼ 9.9 to 13.5) and
34.0 months (95% CI ¼ 27.4 to 42.0) in participants who com-
pleted more than 9 MET hours per week of PA. Among the 126
participants with hormone receptor–negative cancers, no statis-
tically significant association was seen between PA and PFS
(P¼ .31) or OS (P¼ .38). Median PFS and OS were 6.6 months (95%
CI ¼ 5.6 to 7.4) and 13.9 months (95% CI ¼ 11.4 to 18.5), respec-
tively, in participants who completed 0-9 MET hours per week
of PA and 5.9 months (95% CI ¼ 5.5 to 8.9) and 15.6 months (95%
CI ¼ 14.1 to 22.6) in participants who completed more than 9
MET hours per week of PA.
BMI, PA, and Treatment Toxicity
Toxicity information by treatment arm was available for 792
patients with baseline BMI data and 495 patients with baseline
PA data (Table 3). The majority of patients experienced at least
one grade 3 or greater hematologic or nonhematologic toxicity.
There was no statistically significant difference by BMI in the
proportion of patients who reported a grade 3 or higher nonhe-
matologic toxicity in participants treated with paclitaxel
(P¼ .99) or nab-paclitaxel (P¼ .70). However, among participants
treated with ixabepilone, individuals who were overweight or
had obesity were more likely to experience a grade 3 or greater
nonhematologic toxicity than individuals of normal weight
Figure 2. Kaplan-Meier plots of progression-free survival (A) and overall survival (B) by body mass index (BMI). Two-sided stratified log-rank test was used with stratifi-
cation factors including treatment assignment, hormone receptor status, prior taxane, and use of bevacizumab.
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(P¼ .05). There were no statistically significant differences in
rates of hematologic or nonhematologic toxicity by PA.
Given that chemotherapy-induced peripheral neuropathy is
the most prevalent nonhematologic toxicity associated with
taxane treatment, the relationship between BMI and PA and the
incidence of grade 2 or greater neurotoxicity was explored.
Among participants treated with ixabepilone, the incidence of
grade 2 or greater neurotoxicity differed with respect to PA, with
67.5% of individuals completing more than 9 MET hours per
week experiencing neuropathy vs 43.4% in individuals reporting
0-9 MET hours per week (P¼ .009). There were no statistically
significant differences in rates of neurotoxicity by BMI.
Discussion
In the largest study to date evaluating the relationship between BMI
and recreational PA to cancer outcomes in individuals with MBC,
there was no statistically significant relationship between either BMI
or recreational PA and PFS or OS. Although OS was marginally longer
in participants who engaged in higher levels of PA, especially in
those with hormone receptor–positive cancers, these relationships
were not statistically significant. Notably, in this cohort of individu-
als initiating first-line chemotherapy for MBC, the prevalence of
obesity and inactivity were high, with 42.6% of participants
classified as obese and 47.6% engaging in less than an hour of
recreational moderate-intensity PA each week. Although the
majority of study participants experienced chemotherapy tox-
icity, BMI and PA were generally not associated with treatment
toxicity, with the exception of higher rates of toxicity in partic-
ipants with obesity who were treated with ixabepilone and
higher rates of neurotoxicity in participants treated with ixa-
bepilone who engaged in greater amounts of PA.
Our data regarding the lack of relationship between BMI and
PFS and OS are consistent with a pooled analysis looking at the re-
lationship between BMI and cancer outcomes in 489 Italian
patients with MBC participating in 3 clinical trials of first-line
anthracycline and/or taxane-based chemotherapy (12). In that
Table 2. Patient characteristics by baseline physical activity (n¼ 492)
Characteristic
Physical activity MET hours per week
P0-9 (n¼ 338) > 9 (n¼ 154)
Median age (range), y 57 (28-86) 57 (33-83) .29a
Age, No. (%), y .48b
20-49 83 (24.6) 40 (26.0)
50-69 214 (63.3) 101 (65.6)
70 to 80 41 (12.1) 13 (8.4)
Sex, No. (%) .05
Male 3 (0.9) 5 (3.2)
Female 335 (99.1) 149 (96.8)
Race, No. (%) .27b
White 263 (77.8) 127 (82.5)
Black 56 (16.6) 17 (11.0)
Other/unknown 19 (5.6) 10 (6.5)
Taxane as adjuvant therapy, No. (%) .26b
Yes 159 (47.0) 64 (41.6)
No 179 (53.0) 90 (58.4)
Visceral metastases, No. (%) .23b
Yes 268 (79.3) 115 (74.7)
No 69 (20.5) 39 (25.3)
Missing 1 0
Disease-free interval, No. (%) .63b
0 (de novo) 38 (11.2) 14 (9.1)
<1 y 68 (20.1) 38 (24.7)
1 y < disease-free interval < 2 y 36 (10.7) 14 (9.1)
>2 y 196 (58.0) 88 (57.1)
Clinical stage, No. (%) .80b
Not IV 27 (8.6) 13 (9.4)
IV 286 (91.4) 126 (90.6)
Missing 25 15
Tumor subtype, No. (%) .57b
ER and/or PR positive 254 (75.1) 112 (72.7)
ER and PR negative 84 (24.9) 42 (27.3)
ECOG performance, No. (%) <.001b
0 187 (57.2) 112 (75.7)
1 140 (42.8) 36 (24.3)
Missing 11 6
aTwo-sided Wilcoxon rank sum test or Kruskal-Wallis test. ECOG ¼ Eastern Cooperative Oncology Group; ER ¼ estrogen receptor; MET ¼metabolic equivalents of task;
PR ¼ progesterone receptor.
bTwo-sided v2 test.
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analysis, the median PFS was 10.9 months in normal weight indi-
viduals, 13.0 months in overweight individuals, and 12.2 months in
individuals with obesity (P¼ .17). Median OS was 32.0 months in
normal weight individuals, 33.2 months in overweight individuals,
and 30.7 months in individuals with obesity (P¼ .60).
Other reports have evaluated the relationship between BMI
and cancer outcomes in individuals with MBC with mixed
results (8–11). In patients initiating first-line HER2–directed
therapy for MBC, 2 studies did not demonstrate any relationship
between BMI and PFS (8,9), but 1 study did find a relationship
between obesity and higher risk of overall mortality (HR ¼ 1.29,
95% CI ¼ 1.09 to 1.52; P¼ .003) in women treated with pertuzu-
mab with or without ado-trastuzumab emtansine (8). Similarly,
in patients with MBC and brain metastases, 1 study of 84 indi-
viduals with newly diagnosed brain metastases treated with ra-
diation demonstrated a statistically significant shorter OS in
patients with a BMI of 25 kg/m2 or more vs less than 25 kg/m2
(13.7 months vs 30.6 months; P< .001) (10), and a second study
of 228 individuals with MBC and brain metastases did not find a
statistically significant relationship between BMI and OS (10,11).
More work is needed to understand the relationship between
BMI and outcomes in individuals with advanced cancer in these
populations, but our work and the pooled Italian analyses sug-
gest that there is unlikely to be a statistically significant rela-
tionship between BMI and outcomes in the broader population
of individuals with MBC.
Figure 3. Kaplan-Meier plots of progression-free survival (A) and overall survival (B) by physical activity. Two-sided stratified log-rank test was used with stratification
factors including treatment assignment, hormone receptor status, prior taxane, and use of bevacizumab. MET ¼metabolic equivalents of task.
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There is less information regarding PA patterns, and the re-
lationship between PA and outcomes, in individuals with MBC.
Our study suggested that less than one-third of study
participants engaged in recommended levels of weekly recrea-
tional PA, and 47.6% engaged in little or no regular PA at study
entry. Notably, we found that individuals who reported more PA
Figure 4. Kaplan-Meier plots of progression-free survival by physical activity for patients with hormone receptor–negative (a) and hormone receptor–positive disease
(b) and overall survival by physical activity for patients with hormone receptor–negative (c) and hormone receptor–positive disease (D). Two-sided stratified log-rank
tests were used with treatment assignment as the stratification factor. MET ¼metabolic equivalents of task.
Table 3. Proportion of participants with grade 3 or higher toxicity by body mass index and physical activity
Treatment assignment and toxicity category
Body mass index Physical activity (MET hours per week)
(n¼ 792) (n¼ 495)
Normal Overweight Obese P 0-9 >9 Pa
Paclitaxel, No. 74 79 129 115 64
Hematologic, No. (%) 19 (25.7) 19 (24.1) 26 (20.2) .63 27 (23.5) 13 (20.3) .63
Nonhematologic, No. (%) 45 (60.8) 49 (62.0) 79 (61.2) .99 73 (63.5) 40 (62.5) .90
Nab-paclitaxel, No. 71 93 104 120 50
Hematologic, No. (%) 32 (45.1) 52 (55.9) 62 (59.6) .16 69 (57.5) 28 (56.0) .86
Nonhematologic, No. (%) 49 (69.0) 63 (67.7) 76 (73.1) .70 87 (72.5) 34 (68.0) .56
Ixabepilone, No. 64 76 102 106 40
Hematologic, No. (%) 8 (12.5) 6 (7.9) 14 (13.7) .47 12 (11.3) 5 (12.5) .84
Nonhematologic, No. (%) 33 (51.6) 51 (67.1) 71 (69.6) .05 65 (61.3) 23 (57.5) .67
aTwo-sided v2 test. MET ¼metabolic equivalents of task.
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were more likely to have better performance status.
Performance status has been shown to be a predictor of PFS and
OS in cancer patients (18–20), and individuals with better perfor-
mance status are likely to have greater capacity to exercise.
However, exercise interventions have been shown to improve
functional status in cancer patients (21–23), including patients
with advanced disease (24,25), making it difficult to determine
the independent effects of PA and performance status on PFS
and OS. Randomized trials assessing the impact of exercise
interventions on performance status and treatment outcomes
in individuals with MBC will be needed to untangle the complex
relationship between PA and performance status in this patient
population.
Although our data were collected in the setting of a clinical
trial, where treatments were standardized and collection of PFS
and OS outcome data was robust, a number of limitations of our
study should be acknowledged. First, our analyses were based on
a single measure of BMI and PA at the time of study entry, and
thus, we are not able to evaluate the relationship between weight
change or PA performed during trial participation and cancer out-
comes. Second, our sample size for PA analyses was relatively
small, given that collection of these data was initiated after the
trial was underway. Additionally, although these analyses were
preplanned and were adjusted for other known factors that could
impact outcomes such as performance status and patient age,
analyses were not adjusted for multiple comparisons. This is par-
ticularly relevant in the exploratory analyses looking at the rela-
tionship between BMI and PA and toxicity, given the relatively
small sample size and number of comparisons.
In conclusion, BMI and levels of recreational PA at the time
of treatment initiation were not statistically significant prog-
nostic factors in a group of individuals with MBC initiating first-
line chemotherapy. The lack of a statistically significant rela-
tionship between BMI and outcomes in MBC was consistent
with other reports of patients initiating chemotherapy in the
setting of advanced disease. There was some suggestion of lon-
ger OS in individuals who engaged in higher levels of activity,
especially in those with hormone receptor–positive cancer.
More information about the relationship between PA and out-
comes in individuals with advanced disease is needed, espe-
cially given the high rates of inactivity and the potential
benefits of PA in terms of other health outcomes in individuals
with MBC.
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